Citicolin

Quick links to important sections

Citicolin

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Citicolin

Property Description
Active ingredient Citicoline (CDP-Choline)
Form Oral solutions, capsules, tablets, and injection solutions
Pharmacological class Nootropic and Neuroprotector
Common use Supporting brain metabolism and neuronal integrity
Origin Synthetic compound (endogenous intermediate)

Citicoline: Identity, Classification, and Composition

Citicolin is the generic name (INN) for the pharmaceutical substance Cytidine 5'-diphosphocholine, commonly known as CDP-Choline. This compound is classified within the therapeutic class of psychostimulants and nootropics. Citicoline is chemically synthesized but functions as an endogenous intermediate, replicating a naturally occurring molecule essential for cell membrane health. Pharmacological studies have consistently supported that Citicoline functions as a single-ingredient product designed to enhance central nervous system health. This fundamental chemical identity makes the substance clinically recognized for its role in supplying the necessary precursors for the repair of cellular structures.


Available Forms and General Therapeutic Purpose

Citicoline is supplied in multiple dosage forms, including oral solution, capsules, and tablets for ingestion, alongside a sterile solution for injection suitable for both intravenous and intramuscular administration. This variety allows for flexible therapeutic strategies. The compound's primary mechanism involves supporting and preserving neuronal membrane stabilization by facilitating the synthesis of essential structural lipids. The evidence base demonstrates that its use is centered on providing metabolic support during periods of compromised brain function, a positioning that carries extensive international clinical recognition.

Regulatory References

  1. EMA Public Assessment Report

What side effects are possible with Citicolin?

Possible Side Effects and Safety Information

Citicolin is generally considered to have a favorable safety profile and is well-tolerated across various clinical uses. Adverse reactions are typically rare, mild, and transient.

Common and Less Common Adverse Reactions

The most frequently reported side effects involve the gastrointestinal system and central nervous system. These may include:

System-Organ Class Reported Reactions
Gastrointestinal Diarrhea, nausea, stomach pain, epigastric distress
Nervous System Headache, dizziness, sleeplessness (insomnia), fatigue, restlessness
Cardiovascular Hypotension (low blood pressure), tachycardia, bradycardia
Skin/Immune Rash, allergic reactions (rare)

Contraindications and Safety Restrictions

Citicolin is contraindicated in patients with a known hypersensitivity to the active substance or any of its components. It is also restricted for use in individuals diagnosed with hypertonia of the parasympathetic nervous system (increased parasympathetic tone).

Specific Safety Considerations:

  • Persistent Intracranial Hemorrhage: Caution is required in this condition, as higher doses could potentially aggravate an increase in cerebral blood flow. Dosage adjustments or limitations are indicated in regulatory documents.
  • Pregnancy and Lactation: Due to insufficient reliable data regarding safety and efficacy in pregnant and breastfeeding women, use is generally advised only when the potential benefits clearly justify the potential risks.

Overdose and Emergency Response

Overdose Profile and Toxicity

The official regulatory documents regarding Citicoline (CDP-Choline) consistently state that the compound exhibits a very low toxicity profile in humans. Consequently, the appearance of severe intoxication is formally documented as unlikely even in situations where the therapeutic dose has been accidentally exceeded. Because of this established low toxicity, official prescribing information does not list specific clinical manifestations or a defined cluster of symptoms that characterize an overdose scenario. Furthermore, official government labeling does not specify any severe or life-threatening outcomes formally linked to overdose. No particular population-specific risks, such as for the elderly or those with existing organ impairment, are documented in the overdose sections of the regulatory texts.

Required Emergency Actions and Management

Regulatory guidance focuses on procedural management rather than public-facing emergency warnings. When accidental overdose occurs, the mandated course of action described in official documents is to carry out symptomatic therapy. This involves treating any signs that may arise, though they are not specifically defined by the regulator. It is officially documented that no specific antidote is known for Citicoline overdose. The need for medical care is dictated by the requirement to provide supportive treatment, as is standard when any amount beyond the prescribed dose is administered.

Therapeutic Uses of Citicolin

What Citicoline Treats: Main Uses and Benefits

Citicoline is commonly used across key neurotherapeutic domains, including the symptomatic management of cerebrovascular disorders and head injury. The primary therapeutic application may be considered relevant in domains addressing supportive management of cognitive decline and assistance with neurological recovery after acute events.

The medication is relevant in clinical settings that involve supportive symptom management following ischemic stroke and Chronic Cerebrovascular Disorders (CCVD). It is applied to help manage neurological deficits and functional disability during the recovery phase. Citicoline is commonly used to help with symptoms of impaired cognition and memory, particularly those associated with age-related decline and Mild Cognitive Impairment (MCI). It may assist with symptoms related to memory and attention, helping to support the patient’s cognitive status. Furthermore, it may be part of symptomatic management in situations where patients experience symptoms associated with Traumatic Brain Injury (TBI) and is also used as an adjunctive treatment in specific neurodegenerative conditions, like Glaucoma.

Quick Fact: Supports symptomatic management of Impaired Cognition and Functional Disability

Regulatory References

  1. Philippine FDA Product Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Citicolin — Official Regulatory Information

This section describes official population eligibility and restriction status based strictly on regulatory documents, such as the Summary of Product Characteristics (SmPC) and national drug labels.


Category Regulatory Status (Official Labeling)
Populations for whom use is allowed Adults and Older Adults (Geriatric) are the primary populations for whom the drug's use is established in treating approved conditions.
Populations for whom use is contraindicated Patients with known hypersensitivity to the drug or its excipients, and individuals diagnosed with hypertonia of the parasympathetic nervous system.
Age-related eligibility rules Children and Adolescents (Pediatric): Use is generally not established due to limited or insufficient data on safety and efficacy in these age groups.
Pregnancy and lactation eligibility status Not recommended. Use during pregnancy or breastfeeding is restricted and should be considered only if the potential benefit outweighs the potential risk to the fetus or infant, due to a lack of adequate human safety data.
Eligibility-related restrictions Must not be administered with medicines containing meclofenoxate (also known as centrophenoxine). Caution is also advised for use in patients with persistent intracranial bleeding.

Eligibility Classifications (High-Level)

Category Regulatory Status (Official Labeling)
Eligibility severity classification Contraindicated (Absolute Prohibition); Not Recommended / Not Established (Conditional Restriction).
Eligibility-context constraints Constraints are defined by physiological state (parasympathetic hypertonia) and demographic/life stage (pediatric, pregnancy/lactation).

Resulting Eligibility Structure

Official regulatory documents define the eligible population as adults while establishing absolute non-eligibility for those with parasympathetic hypertonia. Furthermore, regulators impose conditional restrictions and a "not recommended" status on the pediatric population and women who are pregnant or lactating due to insufficient safety data, which is a standard regulatory constraint.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define Citicoline's interaction profile based on specific prohibitions and pharmacodynamic effects, primarily concerning other medicinal products.


Documented Drug-Drug Interactions

Interaction Type Interacting Substance Official Regulatory Statement
Contraindicated Combination Meclofenoxate (Clophenoxate) Co-administration is prohibited; the product must not be administered in conjunction with medicaments containing meclofenoxate.
Pharmacodynamic Potentiation Levodopa (L-dopa) Co-administration potentiates the effects of levodopa.

The most stringent interaction constraint is an absolute restriction against combining Citicoline with meclofenoxate-containing products, which is officially classified as an incompatibility in prescribing information. The interaction with levodopa is explicitly documented as a functional enhancement, indicating an officially recognized additive effect on the action of levodopa. Furthermore, some government regulatory documents include an advisory statement that alcohol should not be consumed during the use of this product. No complex pharmacokinetic interactions, such as those involving CYP-mediated enzyme inhibition or induction, are explicitly documented in the official regulatory labels. This profile is restricted to specified co-administration constraints and two clear pharmacodynamic interaction patterns.

Mechanism of Action

How Citicoline Works: Mechanism of Action

Citicoline acts as a precursor to essential cellular components within the central nervous system. Following hydrolysis into its metabolites, choline and cytidine, these molecules are utilized in key intracellular pathways. The choline component is channeled into the Kennedy Pathway (CDP-Choline cycle), facilitating the de novo synthesis of phosphatidylcholine ( PtdCho), the primary phospholipid building block of neuronal and glial cell membranes. This mechanism directly supports membrane structural integrity and fluidity.

Simultaneously, the choline metabolite increases the availability required for the synthesis of the neurotransmitter acetylcholine. Citicoline also acts as a modulator of catecholaminergic activity, influencing the levels of dopamine and norepinephrine in specific brain regions. Further mechanistic actions include the inhibition of PLA2, an enzyme that catalyzes phospholipid breakdown during cellular stress, and the stabilization of mitochondrial function. These protective actions limit neuronal damage by suppressing apoptotic cascades, which collectively modulates synaptic transmission and supports cellular viability.

Dosage and Administration Information

How to Use Citicolin

Citicoline administration follows specific protocols regarding the route, dosage, and frequency. The substance is available in both oral forms, such as tablets and solutions, and parenteral forms, which consist of solutions for Intravenous (IV) and Intramuscular (IM) injection.


Standard Dosing and Frequency

The standard adult daily dose generally ranges from 500 mg to 2000 mg (2 g). For oral administration, common regimens involve taking 500 mg once daily or 1000 mg once daily, or the total daily dose may be divided and administered twice daily. The course of treatment often follows a defined duration, such as six to twelve weeks.


Administration Conditions

Administration Aspect General Instruction
Oral Intake Can be taken with or between meals (where specified).
IV Injection Speed Must be administered very slowly (typically over 3 to 5 minutes).
IV Solution Compatibility Compatible with all IV isotonic solutions and hypertonic glucose solutions.
Contra-Mixture Must not be mixed with medicaments containing meclofenoxate.

Population-Specific Use

For older adults, it is generally indicated that no specific dose adjustment is necessary. While clinical experience in children is limited, the dose for pediatric patients is typically 100 mg two to three times daily using the oral solution form.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Citicolin


Evidence for Recovery after Acute Ischemic Stroke

Research has explored Citicolin's use in the acute phase following an ischemic stroke. Large-scale Randomized Controlled Trials (RCTs) examined patient groups experiencing acute episodes and compared the substance to a placebo. This research primarily monitored outcomes reflecting daily functioning and the severity of neurological deficits.

Findings from large, definitive trials were inconsistent. While some data show patterns related to recovery in analyses of patients who had more severe symptoms, the largest trials overall did not demonstrate a measurement difference in global functional recovery outcomes compared to the placebo. The evidence in this context is inconsistent across studies.


Research in Chronic Cerebrovascular Conditions and Cognitive Function

Studies have explored how this substance was associated with outcomes reflecting cognitive function in conditions like Chronic Cerebrovascular Disorders (CCVD) and Mild Cognitive Impairment (MCI). Research designs included Randomized Controlled Trials and Systematic Reviews that included patients with age-related memory and attention concerns.

The research describes patterns of measured change in cognitive test scores, particularly in aspects like memory and attention. There are limitations because the evidence quality varies across studies, and there is considerable variability in the neurocognitive tests used across different reports. Additionally, there is limited information for long-term outcomes (over one year) in controlled settings.


What Remains Uncertain in the Research Record

Evidence remains limited across several key applications, largely due to inconsistent findings and limitations in the study designs. Specifically, the evidence for acute stroke and Traumatic Brain Injury is characterized by major RCTs that did not demonstrate a measurement difference in primary outcomes. A key uncertainty is the lack of long-term outcomes data; the majority of research explored short-term symptom changes with limited follow-up duration, making it difficult to assess the durability of observed patterns.

Key Studies & References

  1. Choline-Containing Phospholipids in Stroke Treatment: A Systematic Review and Meta-Analysis (Addresses inconsistency and functional recovery outcomes)
  2. Citicoline Fails to Improve Function or Cognition in TBI Patients (The COBRIT trial—key evidence for TBI and inconsistency claim)
  3. Is Citicoline Effective in Preventing and Slowing Down Dementia?—A Systematic Review and a Meta-Analysis (Addresses general cognitive effects and poor study quality)

Frequently Asked Questions (FAQ)

Common questions about Citicolin (FAQ)


Q: Is Citicolin considered a vitamin or a prescription drug in some countries?

Citicoline is not classified as a vitamin. Its regulatory status varies significantly by region: it is considered a prescription medicine in countries like Japan and Italy, but is available as a dietary ingredient or food supplement in the United States and within the European Union. This difference reflects how the substance is regulated in different markets.


Q: How is the action of Citicolin described differently from other choline supplements?

Official information describes Citicolin as unique because it breaks down into two essential components: choline and cytidine. The supply of both of these molecules allows them to be used in separate, important metabolic pathways, supporting cell membrane synthesis and repair.


Q: Is Citicolin known to interact with common pain relievers like acetaminophen or ibuprofen?

Official regulatory documents explicitly require caution only with Meclofenoxate and note a potentiation effect with Levodopa. There are generally no official contraindications or warnings documented for co-administration with common non-prescription pain relievers.


Q: What are the signs that a person should stop using Citicolin and seek medical advice?

Discontinuation of Citicolin may be necessary if signs of hypersensitivity or allergic reaction occur, as this is a listed contraindication in regulatory documents. For severe or persistent adverse effects, such as low blood pressure (hypotension), a discussion with a healthcare provider is generally indicated.


Q: What is the function of the uridine component released when Citicolin is broken down?

According to official documents, Citicolin is metabolized into cytidine, which converts to uridine in the body. This uridine component is important because it can cross the blood-brain barrier and is utilized in processes that help re-synthesize Citicolin and other crucial structural molecules.


Q: Is Citicolin known to cause drowsiness or affect the sleep cycle?

Official labels list nervous system side effects such as sleeplessness (insomnia), dizziness, fatigue, and restlessness. Drowsiness (somnolence) is generally not listed as a common effect associated with the product.


Q: What is the difference in how Citicolin is regulated in the US versus in Europe?

The regulatory status of Citicolin is different across major regions. In some countries within Europe, it is regulated as a prescription medicine, whereas it is often permitted for use as a dietary supplement ingredient in both the United States and the wider European Union.


Q: Why is Citicolin sometimes associated with improved mental clarity?

Official documents explain that the substance works by supporting the structural integrity of neuronal membranes and increasing the availability of the neurotransmitter acetylcholine. These are essential processes for communication between brain cells and overall brain function.


Q: Can Citicolin cause a headache, and if so, why?

Yes, headache is listed on official labels as a possible, but generally rare, adverse reaction involving the nervous system. The specific underlying reason or mechanism for this side effect is not typically detailed in general regulatory information.


Q: Does Citicolin require a prescription, or is it available over the counter in most places?

The classification of Citicolin varies significantly worldwide. In certain countries, it is strictly classified as a prescription medicine, while in other major markets, it is widely available as a dietary supplement ingredient.


Q: Is Citicolin similar in structure to lecithin or other phospholipids?

Citicolin is described in regulatory documents as an endogenous intermediate—a naturally occurring substance—that acts as a precursor in the biosynthesis pathway. This means it is used by the body to make phosphatidylcholine, the main phospholipid building block of neuronal cell membranes.


Q: What is meant by the term 'neuroprotective' as it relates to Citicolin?

The term relates to its documented actions in supporting the structural integrity of neuronal cell membranes. This includes promoting the repair of damaged structures and reducing the breakdown of cell membrane components during periods of cellular stress.


Q: Are there specific food products that should be avoided while using Citicolin?

Official warnings for use relate to the avoidance of alcohol and co-administration with specific medications, such as meclofenoxate. Regulatory documents generally do not list warnings requiring the avoidance of specific food products.


Q: Is there any information on Citicolin interacting with antidepressant or anti-anxiety medications?

Official regulatory documents do not list a contraindication with common antidepressant or anti-anxiety medications. The existing interaction profile is restricted to specific substances like Levodopa and Meclofenoxate.


Q: How long does Citicolin stay in the body after a person stops taking it?

According to pharmacokinetic data in official product information, Citicolin is eliminated from the body in two phases. The elimination half-life for its components has been reported to be approximately 56 to 71 hours through respiration and urinary excretion.

How should Citicolin be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define the storage and handling requirements for citicoline to maintain its stability and ensure environmental protection upon disposal.

Storage & Disposal Entity Map (High-Level) Official Regulatory Requirement
Mandatory storage conditions: Must be stored at a temperature not exceeding 30 C for some dosage forms.
Handling requirements: Must not be used after the expiry date printed on the package.
Child-protection storage requirements: Must be stored out of the sight and reach of children.

Official Disposal Statements:

  • The product must not be thrown away via wastewater or general household waste.
  • The documented procedure for disposal is to ask your pharmacist how to discard unused medicine.

These requirements strictly define the product's storage environment by setting a maximum temperature limit and governing its lifespan via the expiration date. Disposal instructions mandate consultation with a pharmacist and forbid discarding the drug through standard household waste channels.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Citicolin found in:

A-Z Index: